UFT in bladder cancer

ONCOLOGY

Volumn 13, Issue 7 SUPPL., 1999, Pages 112-115

  Kubota, Yoshinobu ^a   Noguchi, Sumio ^a   Hosaka, Masahiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; UFT;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; HUMANS; TEGAFUR; TREATMENT OUTCOME; URACIL; URINARY BLADDER NEOPLASMS;

EID: 0032814035     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Fujii S, Ikenaka K, Fukushima M, et al: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2- tetrahydro-furyl)-5-fluorouracil and level of 5- fluorouracil in rodents. Gann 70:209-214, 1979.
2. Taguchi T, Fume H, Koyama Y, et al: Phase I study of UFT. Jpn J Cancer Chemotherapy 7:966-972, 1980.
3. Taguchi T: Experience with UFT in Japan. Oncology 11(suppl 10):30-34, 1997.
4. Shida K, Yamanaka H, Ito Y, et al: Phase H study of UFT for malignant tumors of urinary organs. Jpn J Cancer Chemotherapy 11:1307- 1314, 1984.
5. Asahi T, Matumura Y, Ozaki Y, et al: Clinical effect of UFT on bladder cancer. Jpn J Cancer Chemotherapy 9:503-507, 1982.
6. Kubota Y, Hosaka M, Fukushima S, et al: Prophylactic oral UFT therapy for superficial bladder cancer. Cancer 71:1842-1845, 1993.
7. Nagamoto A, Kubota Y, Shuin T, et al: Phase II study of oral 5-FU tablet on bladder cancer. Jpn J Cancer Chemotherapy 16:845-850, 1989.
8. Omori H, Matumura Y, Yoshimoto J, et al: Phase II study of oral 5-FU tablet on bladder cancer. Jpn J Cancer Chemotherapy 15:3115- 3120, 1988.
9. Takayama H, Konami T, Konishi T, et al: Studies on 5-FU concentration in serum and bladder tumor tissue after oral administration of UFT. Acta Urologica Japonica 32:1449-1453, 1986.
10. Lentz H J, Leichman CG, Daneneberg K, et al: Thymidilate synthase expression in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182, 1996.